Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeuticsLi Chen(Harvard University), Emmett V. Schmidt(Merck & Co., Inc., Rahway, NJ, USA (United States))BMC CancerFebruary 27, 201310.1186/1471-2407-13-93Cited by 25SaveCiteExport RISWatch citationsRelated PapersSystematic identification of genomic markers of drug sensitivity in cancer cells|Nature|2012|2.6kThe Integrin αvβ3-5 Ligand MFG-E8 Is a p63/p73 Target Gene in Triple-Negative Breast Cancers but Exhibits Suppressive Functions in ER+ and erbB2+ Breast Cancers|Cancer Research|2010|73